Recent advances in the therapy and prevention of CMV infections

Journal of Clinical Virology

Volumn 16, Issue 1, 2000, Pages 25-40

  Garrett Nichols, W ^a,b   Boeckh, Michael ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Cytomegalovirus; Highly active antiretroviral therapy; HIV infected individuals

Indexed keywords

ANTIVIRUS AGENT; BIOCHEMICAL MARKER; CIDOFOVIR; FOMIVIRSEN; FOSCARNET; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; VALACICLOVIR; VIRUS DNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BONE MARROW TRANSPLANTATION; CYTOMEGALOVIRUS INFECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MAINTENANCE THERAPY; MORBIDITY; MORTALITY; PNEUMONIA; PRIORITY JOURNAL; RETINITIS; REVIEW; STEM CELL TRANSPLANTATION;

EID: 0033959463     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6532(99)00065-7     Document Type: Article

References (60)

1. Atkins J.T., Demmler G.J., Williamson W.D. et al. Polymerase chain reaction to detect cytomegalovirus DNA in the cerebrospinal fluid of neonates with congenital infection. J. Infect. Dis. 169:1994;1134-1137.
2. Boeckh M., Boivin G. Quantitation of cytomegalovirus: methodologic aspects and clinical applications. Clin. Micro. Rev. 11:1998;533-554.
3. Boeckh M., Ljungman P. Cytomegalovirus infection in bone marrow transplant recipients. Bowden R.A., Ljungman P., Paya C. Transplant Infections. 1998;215-227 Lippincott-Raven.
4. Boeckh M. Current antiviral strategies for controlling CMV in hematopoietic stem cell transplant recipients: prevention and therapy. Transpl. Infect. Dis. 1:1999;165-178.
5. Boeckh M., Bowden R.A., Gooley T., Myerson D., Corey L. Successful modification of a pp65 antigenemia-based treatment strategy for prevention of CMV disease in allogeneic marrow transplant recipients. Blood. 93:1999;1781-1782. (letter).
6. Boeckh M., Gooley T.A., Myerson D., Cunningham T., Schoch G., Bowden R.A. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood. 88:1996;4063-4071.
7. Boeckh M., Riddell S.R., Cunningham T. et al. Increased incidence of late CMV disease in allogeneic marrow transplant recipients after ganciclovir prophylaxis is due to a lack of CMV-specific T-cell responses. Blood. 88(Suppl. 1):1996;302a.
8. Boeckh M., Zaia J.A., Skettino S., Jung D., Chauncey T., Bowden R.A. A study of the pharmacokinetics, antiviral activity and tolerability of oral ganciclovir for CMV prophylaxis in marrow transplantation. Biol. Blood Marrow Transpl. 4:1998;13-19.
9. Bowden R.A., Slichter S.J., Sayers M. et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood. 86:1995;3598-3603.
10. Brown F., Banken L., Saywell K., Arum I. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers (review). Clin. Pharmacokin. 37(2):1999;167-176.
11. Crippa F, Corey L, Torok-Storb B, Sale G, Chuang El, Boeckh M. Virological, clinical, and ophthalmologic features of cytomegalovirus (CMV) chorioretinitis after hematopoietic stem cell transplantation. Abstract 1946, 39th Interscience Conference of Antimicrobial Agents and Chemotherapy. San Francisco: 1999.
12. Drew W.L., Ives D., Lalezari J.P. et al. Oral ganciclovir as maintenance therapy for cytomegalovirus retinitis in patients with AIDS. N. Engl. J. Med. 333:1995;615-620.
13. Eddleston M., Peacock S., Juniper M., Warrell D.A. Severe cytomegalovirus infection in immunocompetent patients. Clin. Infect. Dis. 24:1997;52-56.
14. Einsele H., Ehninger G., Hebart H. et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood. 86:1995;2815-2820.
15. Emery V.C., Cope A.V., Bowen E.F., Gor D., Griffiths P.D. The dynamics of human cytomegalovirus replication in vivo. J. Exp. Med. 190:1999;1-6.
16. Epstein S.E., Speir E., Zhou Y.F. et al. The role of infection in restenosis and atherosclerosis: focus on cytomegalovirus. Lancet. 348:1996;13-16.
17. Falagas M.E., Arbo M., Ruthazer R. et al. Cytomegalovirus disease is associated with increased cost and hospital length of stay among orthotopic liver transplant recipients. Transplantation. 63:1997;1595-1601.
18. Gane E., Saliba F., Valdecasas G.J. et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group. Lancet. 350:1997;1729-1733.
19. Hibberd P.L., Tolkoff-Rubin N.E., Conti D. et al. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A randomized controlled trial. Ann. Intern. Med. 123:1995;18-26.
20. Ho M. Advances in understanding cytomegalovirus infection after transplantation. Transplant. Proc. 26:1994;7.
21. Holland G.N., Levinson R.D., Jacobsen M.A., Clinical Trials Group Protocol 915 Team AIDS Dose-related difference in progression rates of cytomegalovirus retinopathy during foscarnet maintenance therapy. Am. J. Ophthalmol. 119:1995;576-586.
22. Jacobsen M.A., Causey D., Polsky B. et al. A dose-ranging study of daily maintenance intravenous foscarnet therapy for cytomegalovirus retinitis in AIDS. J. Infect. Dis. 168:1993;444-448.
23. Jacobson M.A. Treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. N. Engl. J. Med. 337:1997;105-114.
24. Jacobson M.A., Wilson S., Stanley H., Holtzer C., Cherrington J., Safrin S. Phase I study of combination therapy with intravenous cidofovir and oral ganciclovir for cytomegalovirus retinitis in patients with AIDS. Clin. Infect. Dis. 98:1999;528-533.
25. Jacobson M.A., Zegans M., Pavan P.R. et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet. 349:1997;1443-1445.
26. Karavellas M.P., Plummer D.J., Macdonald J.C. et al. Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy. J. Infect. Dis. 179:1999;697-700.
27. Lalezari J.P., Stagg R.J., Kupperman B.D. et al. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS: a randomized, controlled trial. Ann. Intern. Med. 126:1998;257-263.
28. Li C.R., Greenberg P.D., Gilbert M.J., Goodrich J.M., Riddell S.R. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood. 83:1994;1971-1979.
29. Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among solid organ transplant recipients. Abstract LB-1, 39th Interscience Conference of Antimicrobial Agents and Chemotherapy. San Francisco: 1999.
30. Ljungman P., Aschan J., Lewensohn-Fuchs I. et al. Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients. Transplantation. 66:1998;1330-1334.
31. Ljungman P., Cordonnier C., Einsele H. et al. Use of intravenous immune globulin in addition to antiviral therapy in the treatment of CMV gastrointestinal disease in allogeneic bone marrow transplant patients. A report from the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transpl. 21:1998;473-476.
32. Ljungman P., Engelhard D., Link H. et al. Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: experience of European Bone Marrow Transplant Group. Clin. Infect. Dis. 14:1992;831-835.
33. Ljungman P., Oberg G., Aschan J. et al. Foscarnet for preemptive therapy of CMV infection detected by a leukocyte-based nested PCR in allogeneic bone marrow transplant patients. Bone Marrow Transpla. 18:1996;565-568.
34. Lowance D., Neumayer H.H., Legendre C.M. et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. New. Engl. J. Med. 340:1999;1462-1470.
35. Martin D.F., Kuppermann B.D., Wolitz R.A., Palestine A.G., Li H., Robinson C.A. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. N. Engl. J. Med. 340:1999;1063-1070.
36. Martin D.F., Parks D.J., Mellow S.D. et al. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant: a randomized controlled clinical trial. Arch. Ophthalmol. 112:1994;1531-1539.
37. Musch D.C., Martin D.F., Gordon J.F., Davis M.D., Kupperman B.D. Ganciclovir implant study group. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. N. Engl. J. Med. 337:1997;83-90.
38. Nagelschmitz J, Moeller JG, Stass H, Wandel C, Kuhlmann J. Safety, tolerability and pharmacokinetics of BAY 38-4766 - a novel non-nucleosidic inhibitor of HCMV replication - in healthy male subjects. Abstract 0945, 39th Interscience Conference of Antimicrobial Agents and Chemotherapy. San Francisco: 1999.
39. Nelson C.T., Demmler G.J. Cytomegalovirus infection in the pregnant mother, fetus and newborn infant. Clin. Perinatol. 24:1997;151-160.
40. Nichols WG, Corey L, Gooley T et al. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic bone marrow or PBSC transplantation: risk factors and outcome, 1999 (submitted for publication).
41. Patel R., Paya C.V. Cytomegalovirus infection and disease in solid organ transplant recipients. Bowden R.A., Ljungman P., Paya C.V. Transplant infections. 1998;Lippincott-Raven, Philadelphia.
42. Perry C.M., Balfour J.A.B. Fomivirsen. Drugs. 57:1999;375-380.
43. Reed E.C., Wolford J.L., Kopecky K.J. et al. Ganciclovir for the treatment of cytomegalovirus gastroenteritis in BMT patients. A randomized, placebo-controlled trial. Ann. Int. Med. 112:1990;505-510.
44. Reinke P., Fietze E., Ode-Hakim S. et al. Late-acute renal allograft rejection and symptomless cytomegalovirus infection. Lancet. 344:1994;1737-1738.
45. Reusser P, Einsele H, Lee J, Infectious Diseases Working Party, European Group for Blood and Marrow Transplantation. Randomized, multicenter open-label trial of foscarnet vs. ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Abstract 1409, 39th Interscience Conference of Antibmicrobial Agents and Chemotherapy. San Francisco: 1999.
46. Salzberger B., Bowden R.A., Hackman R., Davis C., Boeckh M. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of CMV disease: risk factors and outcome. Blood. 90:1997;2502-2508.
47. Sawyer M.D., Mayoral J.L., Gillingham K.J., Kramer M.A., Dunn D.L. Treatment of recurrent cytomegalovirus disease in patients receiving solid organ transplants. Arch. Surg. 128:1993;165-170.
48. Singh N., Yu V., Mieles L. et al. High dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant patients: a randomized trial. Ann. Int. Med. 120:1994;375-381.
49. Smith I.L., Cherrington J.M., Jiles R.E., Freeman W.R., Spector S.A. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J. Infect. Dis. 176:1997;69-77.
50. Spector S.A., McKinley G.F., Lalezari J.P. et al. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group. New. Engl. J. Med. 334:1996;1491-1497.
51. Spector S.A., Wong R., Hsia K., Pilcher M., Stempien M.J. Plasma cytomegalovirus DNA load predicts CMV disease and survival in AIDS patients. J. Clin. Invest. 101:1998;497-502.
52. Studies of Ocular Complications of AIDS Research Group, AIDS Clinical Trials Group. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis, N Engl J Med 1992;326:213-20.
53. Studies of Ocular Complications of AIDS Research Group, AIDS Clinical Trials Group. Foscarnet-ganciclovir cytomegalovirus retinitis trial. 4. Visual outcomes, Ophthalmology 1994;101:1250-61.
54. Studies of Ocular Complications of AIDS Research Group, AIDS Clinical Trials Group. Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: the HPMPC peripheral cytomegalovirus retinitis trial: a randomized, controlled trial, Ann Intern Med 1997;126:264-74.
55. The Oral Ganciclovir European and Australian Cooperative Study Group. Intravenous versus oral ganciclovir: European/Australian comparative study of efficacy and safety in the prevention of cytomegalovirus retinitis recurrence in patients with AIDS, AIDS 1995;9:471-7.
56. Studies of Ocular Complication of AIDS Research Group, AIDS Clinical Trials Group. Combination foscarnet and ganciclovir therapy vs. monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS: the Cytomegalovirus Retreatment Trial, Arch Opthalmol 1996;114:23-33.
57. Toro A.I., Ossa J. PCR activity of cytomegalovirus in healthy CMV-seropositive individuals: does latency need redefinition? Res. Virol. 147:1996;233-238.
58. Tural C., Romeu J., Sirera G. et al. Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in HIV-infected patients. J. Infect. Dis. 177:1998;1080-1083.
59. Vitravene package insert, Isis Pharmaceuticals, 1998.
60. Walter E.A., Greenberg P.D., Gilbert M.J. et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333:1995;1038-1044.